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FOLLOWING the description byKlopp and his colleagues (1950) ofthe treatment
of locally advanced malignant disease by the intra-arterial injection of nitrogen
mustard, considerable interest has been taken in intravascular techniques
developed for the administration of cytotoxic agents. Sullivan, Miller and Sykes
(1959) first described the administration ofthe folic acid antagonist Methotrexate
(amethopterin, 4-amino-N10 methyl pteroylglutamic acid) by continuous intra-
arterial infusion combined with the intra-muscular administration of folinic acid
(Leucovorin). Using this technique it became possible to infuse the tumour area
with a high concentration of the drug for long periods, its severe toxic effects
being prevented by the folinic acid. Variable degrees oftherapeutic success have
been reported (Duff et at., 1961; Westbury et al., 1962; Espiner, Vowles and
Walker, 1962), but there is little detailed information on the effect ofsuchinfusions
upon haemopoiesis.
Freeman (1958, 1962) has studied plasma and urine levels of Methotrexate
following oral and intravascular administration, but the patients were not
receiving folinic acid and the periods of treatment were short. The lack of a
method for the estimation of Methotrexate in the presence of folinic acid has
previously prevented a study of the plasma levels attained during prolonged
infusion, using the combined therapy procedure, and their relationship to haema-
tological changes, local toxicity and clinical results.
In the present study patients with locally advanced malignant disease have
been treated by continuous intra-arterial infusion of Methotrexate combined with
the intermittent, intramuscular administration of folinic acid. A fluorimetric
technique for the estimation of plasma levels of Methotrexate developed by one
ofus (C. Evans) has enabled the plasma levels, together with the urinary excretion,
to be related to the changes observed in the bone marrow and peripheral blood.
MATERIAL AND METHODS
Fourteenpatientswith locallyrecurrent malignant diseaseinthe head and neck
region, the pelvis and the lower limbs were studied (Table I).
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TABLE I.-Compo8ition of Patients
Duration
of
Case Infusion
Number Sex Age Diagnosis Previous therapy Days
1 M . 48 . Squamous cell carcinoma penis . Surgery . 7
Radiation
F . 44 Squamous cell carcinoma cheek . Surgery . 8
Radiation
3 F . 44 Squamous cell carcinoma cervix . Radiation . 6
4 M . 63 . Myxosarcoma of thigh . Surgery . 4
5 . F 57 Adenocarcinoma of colon Surgery . 4
Radiation
6 . F 40 . Squamous cell carcinoma cervix . Radiation . 5
7 . F 67 . Squamous cell carcinoma tongue . Radiation . 5
8 F 54 . Squamous cell carcinoma tongue . Surgery . 5
Radiation
9 M . 47 . Mixed salivary gland tumour Surgery . 5 and 3
Radiation
10 . F 64 Adenocarcinoma of rectum . Nil . 6
11 . F . 56 Squamous cell carcinoma anus . Nil . 5
12 M . 56 Squamous cell carcinoma scrotum Surgery . 6
Radiation
13 . M . 63 . Papillary carcinoma bladder . Radiation . 6
14 . M . 41 . Adenocarcinoma of rectum . Nil . 5
Arterial catheterisation was performed by a technique previously described
(Bond, Clarke and Neal, 1964).
Methotrexate was administered in a total dose of 50 mg. daily by continuous
infusion using a constant infusion pump (Distillers Co. Ltd.; Micro Type " S ").
Doses of 25 mg. in 480 ml. sterile distilled water were given in each 12-hour period.
Folinic acid was given intramuscularly throughout the period of infusion and for
the subsequent 48 hours in a dose of 6 mg. every 6 hours. Infusions varied in
length from 3 to 8 days depending upon the severity oflocal and systemic toxicity.
In 2 cases accidental withdrawal ofthe catheter shortened the proposed course of
treatment.
Haemoglobin estimations and leucocyte and platelet counts were carried out
dailyduringtheperiodofinfusion andthenuntilthevalueshadreturned to normal.
Bone marrowexaminations were performed before infusion in 6 patients andwithin
48 hours after infusion in all but one.
In 10 patients the fasting serum folic acid activity (Lactobacillus casei method:
normal range 5 to 22 m,ug. per ml.) was determined before, and in 5 patients
repeated 24 to 48 hours after infusion.
Using the method of Freeman (1958), the concentration of Methotrexate was
estimated in 24-hour urine samples collected throughout infusion and for the 2
subsequent 24-hour periods. By a modification of the method of Freeman (1957),
the concentration of Methotrexate in plasma was estimated at 24-hour intervals
during and up to 48 hours after infusion.
Modified Methodfor Estimation of Methotrexate in Plasma
Principle
Following the separation ofMethotrexate from the plasma proteins the increase
in fluorescence of Methotrexate on oxidation was measured. The fluorescenceD. P. ROSE, M. R. BOND AND CHRISTINE EVANS
excitation spectra (uncorrected) of oxidised Methotrexate anid oxidised folinic acid
are shown in Fig. 1. At an excitation wavelength of 370 mr/ both oxidised coin-
ponents have a similar fluorescence emission but at an excitation wavelength of
382 ma oxidised Methotrexate has a fluorescence emission, but there is no detect-
able emission from oxidised folinic acid. The increase in the fluorescence of
Methotrexate on oxidation can therefore be measured at excitation wavelenigth
382 m,t without interference due to folinic acid.
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Fig. 1. The fluoreseence excitation spectra (uncorrectedl) of oxidtisedl Mlethotrexate (A)
and oxidise(l folinic acid (B).
Method
Plasma was obtained from oxalated blood and Methotrexate then separated
from the plasma proteins by gel-filtration on Sephadex G-25 (Pharmacia, Uppsala,
Sweden). 1P2 g. ofdry Sephadex G-25 was prepared in a water-swollen particulate
fornm and used as a column 7-5 cm. long and 1 cm. diameter, according to the method
of Flodin (1961). The bed was stabilised over 1 to 2 hours with distilled water
before use.
The elution volumes for plasma proteins and Methotrexate were determined by
passing 1 ml. of normal plasma and 1 ml. of a standard Methotrexate solution
(1 mg. per ml.) through the column, and eluting with distilled water. Fractions
of 1 ml. were collected and the absorbency of proteins at 280 m,u and Metho-
trexate at 370 mu determined (Fig. 2). Methotrexate was eluted in fractions 8-15,
in a total volume of 7 ml. The elution diagrams showed that wbilst the Metho-
trexate fractions (8-15) and the plasma protein fractions (3-7) were effectively
128EFFECT OF METHOTREXATE ON HAEMOPOIESIS
separated, a compound in the plasma absorbing at 280 m, was eluted with the
Methotrexate, but did not interfere with the assay.
1 ml. of plasma was used for each estimation. After separation of the Metho-
trexate fraction on the Sephadex column 0.1 ml. of 5 M acetate buffer was added to
the 7 ml. eluate and the fluorescence (A) measured. The buffered eluate was
oxidised with 0-1 ml. of 4 % KMnO4 and, after standing for 5 minutes, 0-1 ml. of
3 % H202 was added and the fluorescence ofMethotrexate measured after 2 minutes
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Ficso. 2. Elution diagram showing the absorbency of proteins at 28(0 Iimo (A) and of
Methotrexate at 370 inmu (B).
(B). The increase in fluorescence on oxidation was therefore (B A). A plasma
sample obtained before any Methotrexate had been given was used as a blank.
The fluorescence of Methotrexate in the sample was therefore (B. - A) sample
(B - A) blank. Standard reference curves of the variation of fluorescence
intensity with the concentration ofMethotrexate were determined by this method.
RESULTS
Haemoglobin levels
The haemoglobin levels before infusion and the lowest value recorded during
the period of infusion and for the subsequent 7 days are given in Table II. Eight
of the 14 patients showed a fall ofhaemoglobin level greater than 2 g. per 100 ml.,
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TABLE 1I.-Haematological Data
Hb. level Total
g./100 ml. WBC/cu.mm.
C- r
Case Pre- Lowest Pre- Lowest
Number infusion level infusion count
1 10-6 7 9 20,000 1,100
2 11-1 9 7 8,000 1,400
3 13-2 9*3 11.000 2,000
4 13-5 11-4 5,000 2,800
5 10- 7 10-4 6,000 3,000
Platelet count
per cu.mm.
Lowes-t
lymph. Pre- Lowest
count/cu.mm. infusion count
180 260,000 170,000
168 165,000 90,000
294 200,000 60,000
1,456 255,000 120,000
900 265,000 130,000
6 10- 4 10-0 6,000 3,000 1,320 275,000 165,000
7 11*5 10-4 5,000 3,400 600 120,000 120,000
8 14- 1 11 5 10,000 3,400 680 230,000 180,000
9 15.1 12-4 7,000 3,500 420 225,000 195,000
10 13- 1 9-9 17,000 4,000 600 225,000 150,000
11 12-3 8-5 9,000 6,000
12
13
14
15-8 13-6 11,000 6,000
10-9 10-9 8,000 6,000
13- 5 12 6 13,000 8,000
480 430,000 125,000
660 160,000 160,000
540 165,000 165,000
2,700 460,000 130,000
Erythropoiesis
post-infusion
Megaloblasts and
pseudo-megaloblasts
Hypoplastic,
normoblastic
Normoblastic
Hypoplastic,
normoblastic
Transitional megalo-
blasts and pseudo-
megaloblasts
Pseudo-megaloblasts
Transitional
megaloblasts
Transitional megalo-
blasts and pseudo-
megaloblasts
Transitional
megaloblasts
Transitional
megaloblasts
Pseudo-megaloblasts
Normoblastic
Hypocellular
Megaloblastic
and of these 5 became mildly anaemic. In 1 further case (No. 1 in Table I) severe
anaemia developed (Hb 7 9 g. per 100 ml.). This patient, however, was mildly
anaemic before infusion and the bone marrow showed toxic changes.
Leucocyte counts
The total leucocyte count for each patient and the lowest count observed
during or after infusion are given in Table II. Nine patients developed leucopenia
(total count less than 4000 per cu. mm ) within 3 days ofthe end ofinfusion, but a
rise to normal values took place during the next 7 days. A lymphopenia (less
than 1000 lymphocytes per cu. mm.) was observed in 11 patients, in 4 of whom
the total leucocyte count remained within the normal range (Table II). A
neutropenia (less than 1500 neutrophil leucocytes per cu. mm.) occurred in only
2 cases.
Platelet counts
Although definite falls in the platelet counts were observed in 6 cases, thrombo-
cytopenia (less than 100,000 per cu. mm.) occurred in only 2 cases.
Bone marrow examination
All bone marrow examinations performed before infusion showed normoblastic
erythropoiesis. Samples of bone marrow from 9 of 13 patients examined after
infusion contained megaloblasts, pseudomegaloblasts, or transitional megaloblasts
Serum folate
levels
pre-infusion
mpug./ml.
4-7
6-4
18 8
3 0
4-4
5 0
4.1
10.0
8-0
7-4
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anid giant metamyelocytes. Three showed solely normoblastic erythropoiesis,
but in 2 of these the marrow was hypoplastic.
Serumfolic acid activity
The results for 10 patients in whom the serum folic acid activity was assayed
before infusion are included in Table II. Four patients had levels below the
normal range, in two of whom bone marrow examination showed normoblastic
erythropoiesis.
Estimations of serum folic acid activity were carried out within 48 hours of
infusion in 5 patients and in each the serum failed to support the growth of
Lactobacillus casei. Bone marrow examinations performed in 4 of these patients
showed megaloblastic erythropoiesis.
Methotrexate levels in plcsma and urine
The daily plasma concentrations and the 24-hour urinary excretions of Metho-
trexate are given in Table III. In general the plasma concentrations showed a rise
TABLE 11I.-The Plasma and Urinary Concentrations of Methotrexate
During and After Infusion
Patient Days
1 2 3 4 5 6 7 8 9 10
2 . P - . 2-70 3*30 3-60 . 1-70 . 1-80 1-30 . 1-30 2-20 0
U . 26-60 . 88-50 . 71-50 0 . 0 88-0 44*0 23-4 0 0
3 . P . - 1-65. 0-85. 0-90. 0-50. 1-30. 1-25. 0
U . 19-50 .32-40 .37-60. 53-0 .63-0 .40-0 .19-5 . 0
6 . P . 0-45. 1-55. . 0-20. 0-60. 0-40 .0
U . 52-2 . 43-2 . 50-0 . 50-8 38-6 . 21-4 . 0
7 . P . . - . 1-20. 0-40. 0-80. 1-30. 0 . 0
U . 5*40 . 14-40 . 67-50 . 63-50 . 60-20 . 35-30 . 0 . 0
8 . P . - - . 0-55. 0 . 0-30. 0-15. 0 . 0
U . 4*90 . 5-20 . 29-20 . 16-0 70-30 . 52-30 . 19-60 . 0
9 . P . -- . 4-20. 0-30. 0-85. 0-45. 0-05. 0
91 U . 19-2 . 28-0 47-3 .102-0 13-9 . 0 . 0
92 p P 0-85 . 0-60 . 0 . 0-85 . 0-40 . 0 . 0
U . 0 . 38-0 27-2 . 33-6 3-35 . 1-0 . 0
10 . P - . 4-20. 2-10. 1-00. 1-40. 1-50. 1-10. 0
U . 23-1 . 81-0 . 67-0 . 14-9 65-0 . 44-0 - . 0
11 . P . - . 1-35. 3-60. 1-20. 0 . 0
U . 61-0 . 38-0 . 50-0 . 28-8 . 27-4 . 0
12 . P . . 1-0 . 1-0 . 0-75. 0 . 135. 0-8 . 0 . 0
U . 0 . 53-0 32-0 . 45-0 44-0 . 97-0 .100-0 . 53-0 0
13 . P . . 1-05 . 2-80 . 1-60 . 1-80 . 0-40 . 0-60
U . 35-8 . . 34.5 . 61-7 . 57-5 . 48-8 .
Note: Figures in italics indicate levels after infusion.
P = Plasma concentration ,ug./ml.
U = Urinary excretion mg./24 hours.
until the second or third day of infusion and then remained at approximately the
same level until infusion ceased. The rates ofurinary excretion showed a similar
pattern; increasing over a period of 3 to 4 days and then either remaining steady
or diminishing slightly. Following infusion, Methotrexate was not detected inD. P. ROSE, M. R. BOND AND CHRISTINE EVANS
blood or urine after an interval of 24 hours in all but 3 instances irrespective of
the length ofinfusion time. The 3 exceptions consisted of one infusion of 3 days
carried out within 10 days of a previous 5-day infusion and infusions of 5 and 6
days respectively.
DISCUSSION
Methotrexate interferes with folic acid metabolism by competitive inhibition
of the enzymic reduction of pteroylglutamic acid. As a result there is failure of
formation of the folic acid coenzymes concerned in nucleic acid synthesis.
Megaloblastic erythropoiesis induced by the folic acid antagonists has been
observed in the bone marrow of dogs given acutely toxic doses (Thiersch and
Philips, 1949). Within 24 hours abnormalities of the red cell precursors were
present including nuclear remnants, pathological mitoses and megaloblasts.
Chronic intoxication produced similar, but less rapid changes and megaloblasts
were not observed in all cases. Megaloblasts have also beenrdescribed in the bone
marrow ofpatients with acute leukaemia treated by Methotrexate (Wilson, 1951).
In the present study 9 of the 13 patients showed evidence of abnormal erythro-
poiesis. In some instances typical megaloblasts or transitional megaloblasts
were seen, but others showed " pseudo-megaloblasts " or " megaloblastoid "
cells, differing from typical megaloblasts in having a more coarse clumping of the
nuclear chromatin network. Similar abnormalities have been described by
Turner (1962). The observed interference with erythropoiesis, occurring after
4 to 8 days of Methotrexate infusion, illustrates that despite the administration
of folinic acid high levels of Methotrexate must have been reached in the bone
marrow.
Despite the morphological changes in the red cell precursors the short periods
of infusion ensured that severe anaemia was not produced from interference with
nucleic acid synthesis. The circulating leucocytes were more severely affected
than the red cells; the result of their shorter life span, but the leucopenia only
persisted for about one week after discontinuing the infusion. A lymphopenia
occurred in 11 patients, but only 2 developed a neutropenia. These results differ
from those of Condit (1960), who found that a fall in the neutrophil count was
usually responsible for the leucopenia.
Freeman (1962) has suggested that, in some instances, folic acid deficiency
before starting therapy may result in an increased sensitivity to Methotrexate.
In the present study 4 patients had reduced serum folic acid levels before infusion,
but the haematological changes did not differ from those of the rest of the series.
The study of plasma levels of Methotrexate indicate that the total dose given
is of more importance with regard to toxicity than the levels in the blood during
the period of infusion. There was, however, a marked variation in the patients'
susceptibility to Methotrexate. Despite the efficiency of the extraction method
only 80 per cent ofthe infused Methotrexate was recovered from the urine, sugges-
ting prolonged tissue binding as has been reported by Johns et al. (1964).
SUMMARY
1. This paper presents the results ofclinical investigations designed to elucidate
the effects upon haemopoiesis ofprolonged intra-arterial infusions ofMethotrexate
given in conjunction with intermittent intramuscular injections of its antidote,
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Leucovorin. A new fluorimetric technique is described which enabled the estima-
tions of Methotrexate in plasma and urine in the presence of Leucovorin.
2. The investigations were carried out during the treatment of 14 patients with
locally advanced malignant disease of the head and neck, pelvis or lower limbs.
The technique of infusion and drug dosages conformed with standard procedures.
3. Following infusion 9 of 13 patients showed evidence ofbone marrow changes
indicative ofacute toxicity including megaloblastic erythropoiesis. The principal
change in peripheral blood was the rapid development of a leucopenia, due chiefly
to a lymphopenia. Recovery occurred swiftly when infusions ceased. These
findings indicate that the administration of Leucovorin does not prevent high
levels of Methotrexate reaching haemopoietic tissues.
4. Although the techniques of estimating Methotrexate in plasma proved
satisfactory, no relationship between plasma levels, urinary excretion and haemo-
poietic changes were detected. The sensitivity ofpatients to the drug varied in an
unpredictable manner and total dose appeared to govern toxicity rather than
plasma levels or urinary excretion.
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